A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia

South African Medical Journal

Volumn 86, Issue 5, 1996, Pages 549-550

  Hocepied, Alain M L J ^a   Falkson, Carla I ^a   Falkson, Geoffrey ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; FLUDARABINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; PHASE 2 CLINICAL TRIAL; RASH; REMISSION; SOMNOLENCE; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; FATIGUE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; SLEEP DISORDERS; THROMBOCYTOPENIA; VIDARABINE;

EID: 0029979966     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Keating MJ, McLaughlin P, Plunkett W, et al. Fludarabine - present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 1994; 5: suppl 2, S79-S83.
2. French Cooperative Group on Chronic Lymphocytic Leukemia. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. Semin Oncol 1993; 20: 21-23.
3. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
4. Bergmann L, Fenchel K, Jahn B, Mitrou PS, Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993; 4: 371-375.